Immunological approaches as therapy for Alzheimer’s disease

Bibliography

• CARRELL RW, LOMAS DA:Conformational disease. Lancet (1997) 35:134–138.
   Google Scholar
• KAYTOR MD, WARREN ST: Aberrant protein deposition and neurological disease. Biol. Chem. (1999) 274:37507–37510.
   Web of Science ®Google Scholar
• WETZEL R: Mutations and off-pathway aggregation of proteins. Trends Biotechnol. (1994) 12:193–198.
   PubMed Web of Science ®Google Scholar
• KELLY JW: Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure (1997) 5:595–600.
   PubMed Web of Science ®Google Scholar
• MIROY GJ, LAI Z, LASHUEL HA, PETERSON SA, STRANG C, KELLY JVV: Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Nat. Acad. Sci. USA (1996) 93:15051–15056.
   PubMed Web of Science ®Google Scholar
• BLANEY JM, JORGENSEN EC, CONNOLLY ML et al.: Computer graphics in drug design: molecular modeling of thyroid hormone-prealbumin interactions. J. Med. Chem. (1982) 25:785–790.
   PubMed Web of Science ®Google Scholar
• FRAUENFELDER H, PETSKO GA, TSERNOGLOU D: Temperature-dependent X-ray diffraction as a probe ofprotein structural dynamics. Nature (1979) 280:558–563.
   PubMed Web of Science ®Google Scholar
• KARPLUS M, PETSKO GA: Molecular dynamics simulations in biology. Nature (1990) 347:632–639.
   Google Scholar
• SOLOMON B, BALAS N:Thermostabilization of Carboxypeptidase A by interaction with its monoclonal antibodies. Biotechnol and Appl. Biochem. (1991) 14:202–211.
   PubMed Web of Science ®Google Scholar
• KATZAV T, HANAN E, SOLOMON B: Effect of monoclonal antibodies in preventing Carboxypeptidase A aggregation. Appl. Biochem. Biotechnol (1996) 2:227–230.
   Google Scholar
• BLONDS, GOLDBERG M: Partly native epitopes are already present on early intermediates in the folding of tryptophan synthase. Proc. Natl. Acad. Sci. USA (1987) 84:1147–1151.
   PubMed Web of Science ®Google Scholar
• CARLSON JD, YARMUSH ML: Antibody assisted protein refolding. Bio/ Technology (1992) 10:86–91.
   PubMed Web of Science ®Google Scholar
• SOLOMON B, SCHWARTZ F: Chaperone-like effect of monoclonal antibodies on refolding of heat-denatured Carboxypeptidase A. I Moi. Recognit. (1995) 8:72–76.
   PubMedGoogle Scholar
• SILEN JL, AGARD DA: The alpha-lytic protease pro-region does not require a physical linkage to activate the proteasedomain in vivo. Nature (1989) 341:462–464.
   PubMed Web of Science ®Google Scholar
• HEBERT LE, BECKETT LA,SCHERR PA, EVANS DA: Annual incidence of Alzheimer's disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord (2001)15:169–173.
   PubMed Web of Science ®Google Scholar
• SELKOE DJ: The molecular pathology ofAlzheimer's disease. Neuron (1991) 6:487–498.
   PubMed Web of Science ®Google Scholar
• BUSCIGLIO J, LORENZO A, YEH J, YANKNER BA: 3-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron (1995) 14:879–888.
   PubMed Web of Science ®Google Scholar
• •Evidence of involvement of amyloid plaques in neurofibrillary tangle formation.
   Google Scholar
• GOTZ J, PROBST A, SPILLANTINI MG et al: Somatodentritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. (1995) 14:1304–1313.
   PubMed Web of Science ®Google Scholar
• •Evidence of involvement of amyloid plaques in neurofibrillary tangles formation.
   Google Scholar
• LEWIS J, DICKSON DW, UN WL et al:Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 293:1487–1491.
   PubMed Web of Science ®Google Scholar
• •Evidence of involvement of amyloidplaques in neurofibrillaty tangle formation.
   Google Scholar
• HARDY J, DUFF K, HARDY KG,PEREZ-TUR J, HUTTON M: Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. (1998) 1:355–358.
   PubMed Web of Science ®Google Scholar
• •Evidence of involvement of amyloid plaques in neurofibrillaty tangle formation.
   Google Scholar
• HARDY J, ALLSOP D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. (1991) 12:383–388.
   PubMed Web of Science ®Google Scholar
• SELKOE DJ: Amyloid 13 protein and the genetics of Alzheimer's disease. J. Chem. (1996) 271:18295–18298.
   Google Scholar
• HARDY J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. (1998) 1:355–358.
   Google Scholar
• HARDY J, SELKOE DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297:353–356.
   PubMed Web of Science ®Google Scholar
• ••This is an excellent updated review whichprovides comprehensive and timely information on therapeutics based on amyloid hypothesis.
   Google Scholar
• CHARTIER-HARLIN MC,CRAWFORD F, HOULDEN H et al: Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature (1991) 353:844–846.
   PubMed Web of Science ®Google Scholar
• GOATE A, CHARTIER-HARLIN MC, MULLAN M et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349:704–706.
   PubMed Web of Science ®Google Scholar
• MULLAN M, CRAWFORD F, AXELMAN K et al: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. (1992a) 1:345–347.
   PubMed Web of Science ®Google Scholar
• MULLAN M, HOULDEN H, WINDELSPECHT M et al.: A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 15, proximal to the alpha-1-antichymotrypsin gene. Nat. Genet. (1992b) 2:340–342.
   PubMed Web of Science ®Google Scholar
• LEVY-LAHAD E, WASCO W,POORKAJ P et al: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 269:973–977.
   PubMed Web of Science ®Google Scholar
• SHERRINGTON R, ROGAEV El, LIANG Y et al.: Cloning of a gene bearing missense mutations in early-onsetAlzheimer's disease. Nature (1995) 375:754–760.
   PubMed Web of Science ®Google Scholar
• SABBAGH MN, GALASKO D, THAL LJ: 13-Amyloid and treatment opportunities for Alzheimer's disease. A/zheimer'sDis. Rev (1998) 3:1–19.
   Google Scholar
• MAGGIO JE, MANTYH PW: Brain amyloid - a physicochemical perspective. Bruin Pathol (1996) 6:147–162.
   PubMed Web of Science ®Google Scholar
• •This study suggests in vitro modulation of p-amyloid formation by various external factors.
   Google Scholar
• KIRSHENBAUM K, DAGGETT V: pH-dependent conformations of the amyloid 13 (1-28) peptide fragment explored using molecular dynamics. Biochemistry (1995) 34:7629–7639.
   PubMed Web of Science ®Google Scholar
• BARROW CJ, ZAGORSKI MG: Solution structures of 13-peptide and its constituent fragments: relation to amyloid deposition. Science (1991) 253:179–182.
   PubMed Web of Science ®Google Scholar
• SOTO C, CASTANO EM,FRANGIONE B, INESTROSA, NC: The a-helical to 13-strand transition in the amino-terminal fragment of the amyloid 13-peptide modulates amyloid formation.Biol. Chem. (1995) 270:3063–3067.
   Web of Science ®Google Scholar
• SOTO C, KINDY MS, BAUMANN M, FRANGIONE B: Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun. (1996) 226(3):672–680.
   PubMed Web of Science ®Google Scholar
• LORENZO A, YANKNER BA: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Nati Acad. Sci. USA (1994) 1:12243–12247.
   Google Scholar
• HOWLETT, DR, JENNINGS KH, LEE DC et al.: Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration (1995) 4:23–32.
   PubMedGoogle Scholar
• WISNIEWSKI T, CASTANO EM, GOLABEK A, VOGEL T,FRANGIONE B: Acceleration of Alzheimer's fibril formation by apolipoprotein E M vitro. Am. j Pathol (1994) 145(5):1030–1035.
   PubMed Web of Science ®Google Scholar
• SOLOMON B, KOPPEL R, HANAN E, KATZAV T: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer's 13-amyloid peptide. Proc. Nati Acad. Sci. USA (1996) 93(1):452–455.
   PubMed Web of Science ®Google Scholar
• ••This is the first demonstration that mAbscan prevent amyloid formation.
   Google Scholar
• SOLOMON B, KOPPEL R, FRANKEL D, HANAN-AHARON E:Disaggregation of Alzheimer p-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA (1997) 94:4109–4112.
   PubMed Web of Science ®Google Scholar
• ••This is the first demonstration that site-directed antibodies dissolve already formed amyloid fibrils.
   Google Scholar
• HANAN E, SOLOMON B: Protective effect of monoclonal antibodies against Alzheimer's 13-amyloid aggregation. Amyloid: Int. j Exp. Clin. Invest. (1996) 3:130–133.
   Google Scholar
• FRENKEL D, SOLOMON B,BENHAR I: Modulation of Alzheimer's 13-amyloid neurotoxicity by site-directed single-chain antibody.' Neuroimmunol (2000) 106:23–31.
   PubMed Web of Science ®Google Scholar
• •Antibodies devoid of Fc region exhibit anti-aggregating properties preventing Ap neurotoxicity.
   Google Scholar
• FRENKEL D, BALASS M,SOLOMON B: N-terminal EFRH sequence of Alzheimer's 13-amyloid peptide represents the epitope of its anti-aggregating antibodies. Neuroimmunol (1998) 8:85–90.
   Google Scholar
• FRENKEL D, BALASS M, KACHALSKY-KATZIR E, SOLOMON B: High affinity binding of monoclonal antibodies to the sequential epitope EFRH of 13-amyloid peptide is essential for modulation of fibrillar aggregation. I Neuraimmuna (1999) 95:136–142.
   PubMed Web of Science ®Google Scholar
• •The study emphasises the key role of EFRH sequence in modulation of AP conformation.
   Google Scholar
• VAN LEUVEN F: Single and multiple transgenic mice as models for Alzheimer's disease. Frog. Neurobiol (2000) 61(3):305–312.
   Google Scholar
• MOORE CL, WOLFE MS: Inhibition of 13-amyloid formation as a therapeutic strategy. Expert Opin. Ther. Patents (1999) 9(2):135–146.
   Web of Science ®Google Scholar
• GAMES D, ADAMS D,ALESSANDRINI R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 373:523–527.
   Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-I3 attenuates Alzheimer's disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
   PubMed Web of Science ®Google Scholar
• ••First in vivo demonstration that anti*arnyloid antibodies reduce amyloid plaque in transgenic mice.
   Google Scholar
• WEINER HL, LEMERE CA, MARON R et al.: Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.Ann. Neurol (2000) 48:567–579.
   PubMed Web of Science ®Google Scholar
• LEMERE CA, MARON R,SPOONER ET et al.: Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PDAPP mice. Ann. NY Acad. Sci. (2000) 920:328–331.
   Google Scholar
• LEMERE CA, MARON R, SELKOE DJ, WEINER H: Nasal vaccination with 13-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. (2001) 20:705–711.
   PubMed Web of Science ®Google Scholar
• GURWITZ D: Immunization for Alzheimer's disease: yet closer to clinical trials. Trends Immuno1(2001)22(10):542–543.
   Google Scholar
• SIGURDSSON EM, SCHOLTZOVA H, MEHTA PD, FRANGIONE B, WISNIEWSKI T: Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am.! Pathol (2001) 159:439–447.
   PubMed Web of Science ®Google Scholar
• HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative memory deficits, A13 elevation, and amyloid plaques in transgenic mice.Science (1996) 274:99–102.
   PubMed Web of Science ®Google Scholar
• FRENKEL D, KATZ 0, SOLOMON B: Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc. Nati Acad. Sci. USA(2000) 97:11455–11459.
   PubMed Web of Science ®Google Scholar
• SCOTT JK, SMITH GP: Searching for peptide ligands with an epitope library.Science (1990) 249:386–390.
   PubMed Web of Science ®Google Scholar
• SCOTT JK: Discovering peptide ligands using epitope libraries. Trends Biochem Sci(1992) 17(7):241–245.
   PubMed Web of Science ®Google Scholar
• GREENWOOD J, WILLIS EA, PERHAM NR: Multiple display of foreign peptides on a filamentous bacteriophage.Mo/. Biol. (1991) 220:821–827.
   PubMed Web of Science ®Google Scholar
• WILLIS EA, PERHAM NR, WRAITH D: Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage. Gene (1993) 128:79–83.
   PubMed Web of Science ®Google Scholar
• BASTEIN N, TRUDE M, SIMARD C: Protective immune responses induced by the immunization of mice with recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology (1997) 234:118–122.
   PubMed Web of Science ®Google Scholar
• SOLOMON B, FRENKEL D: Vaccination towards prevention and treatment of Alzheimer's disease. Drugs of Today (2000) 36(9):655–663.
   PubMed Web of Science ®Google Scholar
• FRENKEL D, KARIV N, SOLOMON B: Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine Elsevier (2001) 19:2615–2619.
   PubMed Web of Science ®Google Scholar
• FRENKEL D, SOLOMON B: Towards Alzheimer's beta-amyloid vaccination.Biologicals (2001) 29:243–247.
   PubMed Web of Science ®Google Scholar
• FRENKEL D, DEWACHTER I, VAN LEUVEN, SOLOMON B: Reduction of A13 amyloid by EFRH-phage immunization. Vaccine (2002) In Press.
   Google Scholar
• MOECHARS D, DEWCHTER I, LORENT K et al.: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem.(1999) 274:6483–6492.
   PubMed Web of Science ®Google Scholar
• BARD F, CANNON C, BARBOUR R et al.: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. (2000) 6:916–920.
   PubMed Web of Science ®Google Scholar
• ••First evidence that peripheraladministration of antibodies against beta-peptide cross BBB, decorate and dissolve plaque.
   Google Scholar
• BACSKAI BJ, KAJDASZ ST, CHRISTIE RH et al.: Imaging of amyloid-B deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. (2001) 7:369–372.
   PubMed Web of Science ®Google Scholar
• ••In vivo targeting of amyloid plaques by mikb and visualisation of clearance of plaque.
   Google Scholar
• DEMATTOS RB, BALES KR,CUMMINS DJ, DODART JC, PAUL SM, HOLTZMAN DM: Peripheral anti-A13 antibody alters CNS and plasma A13 clearance and decreases brain A13 burden in a mouse model of Alzheimer's disease. Proc. Nati Acad. Sci. USA (2001) 17:8850–8855.
   Google Scholar
• JANUS C, PEARSON J, MCLAURIN J et al.: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979–982.
   PubMed Web of Science ®Google Scholar
• •First demonstration of correlation between improved behaviour and vaccination against ABP.
   Google Scholar
• MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: A beta peptide vaccination prevents memory loss in ananimal model of Alzheimer's disease. Nature (2000) 408:982–985.
   PubMed Web of Science ®Google Scholar
• •First demonstration of correlation between improved behaviour and vaccination against ABP.
   Google Scholar
• HOLCOMB L, GORDON MN, MCGOWAN E et al.: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. (1998) 4:97–100.
   PubMed Web of Science ®Google Scholar
• DODART JC, BALES KR, GANNON KS et al.: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. (2002) 5(5):452–457.
   PubMed Web of Science ®Google Scholar
• WYSS-CORAY T, LIN C, YAN F et al.: TGF-betal promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. (2001) 7(5):612–874.
   PubMed Web of Science ®Google Scholar
• BACSKAI BJ, KAJDASZ ST, MEGAN E et al.: Non-fc-mediated mechanisms are involved in clearance of amyloid-I3 in vivo by immunotherapy. Neurosci. (2002) 22(18):7873–7878.
   PubMed Web of Science ®Google Scholar
• DEMATTOS RB, BALES KR, CUMMINS DJ et al.: Brain to plasma amyloid-I3 efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 295:2264–2267.
   PubMed Web of Science ®Google Scholar
• HUANG F, BUTTINI M, WYSS-CORAY T et al: Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am. .1. Pathol. (1999) 155:1741–1747.
   PubMed Web of Science ®Google Scholar
• BORNEMANN KD,WIEDERHOLD KH, PAULI C et al: Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. Athol (2001) 158:63–73.
   PubMed Web of Science ®Google Scholar
• MUNCH G, THOME J, FOLEY P, SCHINZEL R, RIEDERER P: Advanced glycation endproducts in ageing and Alzheimer's disease. Thalia Res. Rev (1997) 23:134–143.
   Google Scholar
• TABATON M, PERRY G, SMITH M et al.: Is amyloid beta-protein glycated in Alzheimer's disease? NeuroReport. (1997) 8:907–909.
   Google Scholar
• SCHENK D, SEUBERT P,CICCARELLI RB: Immunotherapy with I3-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. (2001) 20:679–681.
   PubMed Web of Science ®Google Scholar
• SOLOMON B: Imunotherapeutic strategies towards prevention and treatment of Alzheimer's disease. DNA and Cell Biology (2001) 20:697–703.
   PubMed Web of Science ®Google Scholar
• TAKAI T: Roles of Fc receptors in autoimmunity. Nature Reviews (2002) 2:580–592.
   Web of Science ®Google Scholar
• SAMUELSSON A, TOWERS TL, RAVETCH JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 291:484–486.
   PubMed Web of Science ®Google Scholar
• FRENKEL D, SOLOMON B: Filamentousphage as vector-mediated antibody delivery to the brain. Proc. Natl. Acad. Sci. USA (2002) 99:5675–5679.
   PubMed Web of Science ®Google Scholar
• http://www.elan.com/News/ 03012002.asp?ComponentID=2404&Sour cePageID=149 'Elan and Wyeth provide update on status of Alzheimer's collaboration'.
   Google Scholar
• http://www.elan.com/./ ClinicalTrialInfo.asp?ComponentID=926& SourcePageID=148 08105/2002 Clinical Trial Information Related to AN–1792.
   Google Scholar
• http://www.washingtonpost.com/wp-dy./ A48989-2002Feb21.htm Rick Weiss, Washington Post Staff Writer 'Test of Alzheimer's vaccine is halted'.
   Google Scholar
• http://www.the-scientist.com/yr 192002/apr/ steinberg_p22020401.html The Scientist. Companies Halt First Alzheimer Vaccine Trial.
   Google Scholar